Answers are grounded in this paper and cite their sources.
Lay Summary A pediatric patient with Crohn’s disease refractory to anti-tumor necrosis factor therapy, vedolizumab, ustekinumab, and 6-mercaptopurine achieved rapid clinical remission with upadacitinib. This is the first report of successful use of upadacitinib in pediatric inflammatory bowel disease.
No takes yet. Share an insight, caveat, or question.
Lauren V. Collen (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: